Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

被引:74
作者
Beh, Chaw Yee [1 ]
Prajnamitra, Ray Putra [1 ]
Chen, Li-Lun [1 ]
Hsieh, Patrick Ching-Ho [1 ]
机构
[1] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan
关键词
biomimetic; active targeting; nanoparticles; cancer therapy; immunotherapy; imaging; MEMBRANE-COATED NANOPARTICLES; HEPARAN-SULFATE PROTEOGLYCANS; VIRUS-LIKE PARTICLES; HUMAN SERUM-ALBUMIN; DRUG-DELIVERY; MACROMOLECULAR THERAPEUTICS; VASCULAR-PERMEABILITY; MACROPHAGE-MEMBRANE; TUMOR; RECEPTOR;
D O I
10.3390/molecules26165052
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biomimetic nanoparticles have recently emerged as a novel drug delivery platform to improve drug biocompatibility and specificity at the desired disease site, especially the tumour microenvironment. Conventional nanoparticles often encounter rapid clearance by the immune system and have poor drug-targeting effects. The rapid development of nanotechnology provides an opportunity to integrate different types of biomaterials onto the surface of nanoparticles, which enables them to mimic the natural biological features and functions of the cells. This mimicry strategy favours the escape of biomimetic nanoparticles from clearance by the immune system and reduces potential toxic side effects. Despite the rapid development in this field, not much has progressed to the clinical stage. Thus, there is an urgent need to develop biomimetic-based nanomedicine to produce a highly specific and effective drug delivery system, especially for malignant tumours, which can be used for clinical purposes. Here, the recent developments for various types of biomimetic nanoparticles are discussed, along with their applications for cancer imaging and treatments.
引用
收藏
页数:27
相关论文
共 142 条
[1]   ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics [J].
Arteaga, Carlos L. ;
Engelman, Jeffrey A. .
CANCER CELL, 2014, 25 (03) :282-303
[2]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[3]   The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence [J].
Barker, Holly E. ;
Paget, James T. E. ;
Khan, Aadil A. ;
Harrington, Kevin J. .
NATURE REVIEWS CANCER, 2015, 15 (07) :409-425
[4]   How rapid advances in imaging are defining the future of precision radiation oncology [J].
Beaton, Laura ;
Bandula, Steve ;
Gaze, Mark N. ;
Sharma, Ricky A. .
BRITISH JOURNAL OF CANCER, 2019, 120 (08) :779-790
[5]   Engineering protein nanocages as carriers for biomedical applications [J].
Bhaskar, Sathyamoorthy ;
Lim, Sierin .
NPG ASIA MATERIALS, 2017, 9 :e371-e371
[6]  
Bhatia S., 2016, NATURAL POLYM DRUG D, P33
[7]   Artificial intelligence in cancer imaging: Clinical challenges and applications [J].
Bi, Wenya Linda ;
Hosny, Ahmed ;
Schabath, Matthew B. ;
Giger, Maryellen L. ;
Birkbak, Nicolai J. ;
Mehrtash, Alireza ;
Allison, Tavis ;
Arnaout, Omar ;
Abbosh, Christopher ;
Dunn, Ian F. ;
Mak, Raymond H. ;
Tamimi, Rulla M. ;
Tempany, Clare M. ;
Swanton, Charles ;
Hoffmann, Udo ;
Schwartz, Lawrence H. ;
Gillies, Robert J. ;
Huang, Raymond Y. ;
Aerts, Hugo J. W. L. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (02) :127-157
[8]   Platelet Immunoreceptor Tyrosine- Based Activation Motif ( ITAM) Signaling and Vascular Integrity [J].
Boulaftali, Yacine ;
Hess, Paul R. ;
Kahn, Mark L. ;
Bergmeier, Wolfgang .
CIRCULATION RESEARCH, 2014, 114 (07) :1174-1184
[9]   Gadolinium-Labeled Ferritin Nanoparticles as T1 Contrast Agents for Magnetic Resonance Imaging of Tumors [J].
Cai, Yao ;
Wang, Yuqing ;
Zhang, Tongwei ;
Pan, Yongxin .
ACS APPLIED NANO MATERIALS, 2020, 3 (09) :8771-8783
[10]   Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer [J].
Cao, Haiqiang ;
Dan, Zhaoling ;
He, Xinyu ;
Zhang, Zhiwen ;
Yu, Haijun ;
Yin, Qi ;
Li, Yaping .
ACS NANO, 2016, 10 (08) :7738-7748